

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

25 May 2023 (25.05.2023)



(10) International Publication Number

WO 2023/089007 A1

(51) International Patent Classification:

A01N 37/46 (2006.01) A01N 47/28 (2006.01)

A01N 43/72 (2006.01) A01N 53/00 (2006.01)

A01N 43/82 (2006.01) A01P 3/00 (2006.01)

A01N 43/56 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2022/082228

(22) International Filing Date:

17 November 2022 (17.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21209290.2 19 November 2021 (19.11.2021) EP

(71) Applicant: SYNGENTA CROP PROTECTION AG

[CH/CH]; Rosentalstrasse 67, 4058 Basel (CH).

(72) Inventors: LOISELEUR, Olivier; Schaffhauserstrasse, 4332 Stein (CH). WOLF, Hanno Christian; Schaffhauserstrasse, 4332 Stein (CH).

(74) Agent: SYNGENTA IP; Rosentalstrasse 67, 4058 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(54) Title: FUNGICIDAL COMPOSITIONS

(57) Abstract: A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B), wherein component (A) is Aureobasidin, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.



WO 2023/089007 A1

82506-F.F

FUNGICIDAL COMPOSITIONS


The present invention relates to novel fungicidal compositions for the treatment of phytopathogenic diseases of useful plants, especially phytopathogenic fungi, and to a method of controlling such diseases, and/or fungi, on useful plants.

Whilst many fungicidal compounds, belonging to various different chemical classes, have been/are being developed for use as fungicides in crops of useful plants, crop tolerance and activity against particular phytopathogenic fungi do not always satisfy the needs of agricultural practice in many respects. WO 2018/102345 discloses use of Aureobasidin A as an agricultural fungicide to treat, prevent or control fungal infections in plants and seeds. Aureobasidin A is an antifungal cyclic depsipeptide antibiotic produced by *Aureobasidium pullulans*. See, for instance, Takesako et al., *The Journal of Antibiotics*, 1991, 44, 919-924.

However, there is a continuing need to find new compositions having superior biological properties for use in controlling or preventing infestation of plants by phytopathogenic fungi. For example, compositions possessing a broader spectrum of activity, improved crop tolerance, synergistic interactions or potentiating properties, or compositions which display a more rapid onset of action or which have longer lasting residual activity or which enable a reduction in the number of applications and/or a reduction in the application rate of the compounds and compositions required for effective control of a phytopathogen, thereby enabling beneficial resistance-management practices, reduced environmental impact and reduced operator exposure.

The use of compositions comprising mixtures of different fungicidal compounds possessing different modes of action can address some of these needs (eg, by combining fungicides with differing spectrums of activity).

According to the present invention, there is provided a fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) comprises a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof.




(I-A1); and

component (B) is selected from the group consisting of histone deacetylase inhibitors:

ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate, N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(E)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(Z)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoic acid, ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazole-4-carboxylate, or ethyl 1-[[4-[[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carboxylate,

or a salt, enantiomer, tautomer or N-oxide thereof.

Preferably, the fungicidal composition comprises a mixture of components (A) and (B) as active ingredients, wherein component (A) comprises a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof:




and

component (B) is selected from the group consisting of histone deacetylase inhibitors:

ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, and N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, or a salt, enantiomer, tautomer or N-oxide thereof.

Disclosed herein is a composition comprising a mixture of component (A) and (B) wherein component A comprises cyclic depsipeptides of formula (I) or a stereoisomer thereof:

4



wherein

R¹ is methyl, ethyl, 1-hydroxyethyl or 2-hydroxyethyl;

A¹ is an α -amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal) and L-valine (L-Val) residues;

A² is an α -amino acid residue selected from the group consisting of L-phenylalanine (L-Phe), ortho-fluoro-L-phenylalanine (L-o-FPhe), meta-fluoro-L-phenylalanine (L-m-FPhe), L-tyrosine (L-Tyr), L-cyclohexylalanine (L-Cha), O-acetyl-L-tyrosine [L-Tyr(Ac)], O-n-hexanoyl-L-tyrosine [L-Tyr(n-hexanoyl)], O-benzoyl-L-tyrosine [L-Tyr(Bzl)] and persephanine residues;

A³ is an α -amino acid residue selected from the group consisting of N-methyl-L-phenylalanine (L-MePhe), L-phenylalanine (L-Phe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), ortho-fluoro-N-methyl-L-phenylalanine (L-o-F-MePhe), meta-fluoro-N-methyl-L-phenylalanine (L-m-F-MePhe), para-fluoro-N-methyl-L-phenylalanine (L-p-F-MePhe), meta-bromo-N-methyl-L-phenylalanine (L-m-Br-MePhe), para-bromo-N-methyl-L-phenylalanine (L-p-Br-MePhe), meta-iodo-N-methyl-L-phenylalanine (L-m-I-MePhe), para-iodo-N-methyl-L-phenylalanine (L-p-I-MePhe), 3-phenyl-N-methyl-L-phenylalanine, 4-phenyl-N-methyl-L-phenylalanine, 3-(4-fluorophenyl)-N-methyl-L-phenylalanine, 4-(4-fluorophenyl)-N-methyl-L-phenylalanine, 3-(4-pyridinyl)-N-methyl-L-phenylalanine, 4-(4-pyridinyl)-N-methyl-L-phenylalanine, 3-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-4-pyridinyl)-N-methyl-L-phenylalanine, 3-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 3-[4-(piperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(piperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine, 3-[4-(4-methylpiperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(4-methylpiperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine, β -oxo-N-methyl-L-phenylalanine (L- β -oxo-MePhe), β -acetoxo-N-methyl-L-phenylalanine (L- β -AcO-MePhe), N-methyl-L-tyrosine (L-MeTyr), O-methyl-N-methyl-L-tyrosine [L-MeTyr(Me)], N-methyl-L-alanine (L-MeAla), N-methyl-L-serine (L-MeSer), N-methyl-D-phenylalanine (D-MePhe), N-methyl-D-alanine (D-MeAla), N-methyl-D-valine (D-MeVal), N-methyl-D-serine (D-MeSer), N-methyl-sarcosine (MeSar) and N-methyl-L-serine (L-MeSer) residues;

A⁴ is an α -amino acid residue selected from the group consisting of L-proline (L-Pro), L-thioproline (L-SPro) and 4-hydroxy-L-proline (L-4Hyp) residues;

A⁵ is an α -amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle), L-norvaline (L-Nva) and L-valine (L-Val) residues;

5 A⁶ is an α -amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), N-methyl-L-allo-isoleucine (L-MeAlle) and L-valine (L-Val) residues;

A⁷ is an α -amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and

10 A⁸ is an α -amino acid residue selected from the group consisting of β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal), γ -hydroxy-N-methyl-L-valine (L- γ -OH-MeVal), N-methyl-L-valine (L-MeVal), L-valine (L-Val), N-methyl-2,3-didehydro-L-valine (L-MeDH_{2,3}Val), N-methyl-3,4-didehydro-L-valine (L-MeDH_{3,4}Val), N-methyl-L-phenylalanine (L-MePhe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), N-methyl-L-threonine (L-MeThr), sarcosine (Sar) and N, β -dimethyl-L-aspartic acid (L-N, β -MeAsp) residues; and

15 component (B) is selected from the group consisting of histone deacetylase inhibitors:
ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-
20 [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, N,N-dimethyl-1-[[4-[5-
25 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate, N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methyl-4-[5-
30 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(E)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(Z)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 4-[5-
35 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoic acid, ethyl 1-[[4-[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazole-4-carboxylate, or ethyl 1-[[4-[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carboxylate,

or a salt, enantiomer, tautomer or N-oxide thereof.

In general, the weight ratio of component (A) to component (B) may be from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.

5 In some preferred embodiments of the invention, the weight ratio of component (A) to component (B) may be of 1:1, or 1:2, or 1:4, or 1:8, or 2:1, or 4:1, or 8:1, or 16:1, or 20:1, or 1:200, or 1:100, or 1:50, or 1:25, or 1:20, or 1:12.5, or 1:10, or 1:6.2, or 1:5, or 1:2.5, or 2:1, or 3:1, or 10:1, or 20:1, or 30:1.

10 According to a second aspect of the invention, there is provided a method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition as defined according to the invention. Preferred is a method which comprises applying to the useful plants or to the locus thereof a composition according to the invention, more preferably to the useful plants. Further preferred is a method which comprises
15 applying to the propagation material of the useful plants a composition according to the invention.

According to a third aspect of the invention, there is provided the use of a composition comprising component (A) and component (B) as defined according to the invention as a fungicide.

20 It has been found that the use of a compound of component (B) and, optionally, component (C) in combination with the compound of formula (I-A-1) surprisingly and substantially may enhance the effectiveness of the latter against fungi, and vice versa. Additionally, the use of the compositions of the invention may be effective against a wider spectrum of such fungi than can be combated with the individual active ingredients when used alone.

The benefits provided by certain fungicidal compositions according to the invention may also include, *inter alia*, advantageous levels of biological activity for protecting plants against diseases that
25 are caused by fungi or superior properties for use as agrochemical active ingredients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability).


As used herein, the term "cyclic depsipeptide" refers to a cyclic peptide consisting, in sequence, of units derived from a 2-hydroxy-3-methylalkanoic acid and from the α -aminoacids A¹, A², A³, A⁴, A⁵,
30 A⁶, A⁷ and A⁸, wherein the α -aminoacid residue A⁸ is bonded to the -OCH(CH(CH₃)R¹) moiety of the 2-hydroxy-3-methylalkanoic acid through an ester group to form a -C(=O)OCH(CH(CH₃)R¹) moiety, and wherein the α -aminoacid residues A¹, A², A³, A⁴, A⁵, A⁶, A⁷ and A⁸ are linked to each other through peptide bonds. The 2-hydroxy-3-methylalkanoic acid can be 2(R)-hydroxy-3(R)-methylpentanoic acid or 2(R)-hydroxy-3-methylbutanoic acid.

35 As used herein, the term "hydroxyl" or "hydroxy" means an -OH group.

As used herein, the term "C₁-C₄ alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to four carbon atoms, and which is attached to the rest of the molecule by a single bond. Examples of C₁-C₄

alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, and 1,1-dimethylethyl (t-butyl). A “C₁-C₄ alkylene” group refers to the corresponding definition of C₁-C₄ alkyl, except that such radical is attached to the rest of the molecule by two single bonds. Examples of C₁-C₄ alkylene groups are methylene (-CH₂-) and hydroxymethylene (-CH(OH)-).

5 Disclosed herein is component (A) which comprises one or more cyclic depsipeptides of formula (I-A):



wherein

10 R¹ is methyl or ethyl;

each of X^1 , X^2 and X^3 is hydrogen, or X^1 , X^2 and X^3 are hydrogen, fluorine or hydroxyl, with the proviso that only one of X^1 , X^2 and X^3 is fluorine or hydroxyl;

X⁴ is S, methylene or hydroxymethylene;

A³ is an α -amino acid residue selected from the group consisting of N-methyl-L-phenylalanine (L-MePhe), L-phenylalanine (L-Phe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), ortho-fluoro-N-methyl-L-phenylalanine (L-o-F-MePhe), meta-fluoro-N-methyl-L-phenylalanine (L-m-F-MePhe), para-fluoro-N-methyl-L-phenylalanine (L-p-F-MePhe), meta-bromo-N-methyl-L-phenylalanine (L-m-Br-MePhe), para-bromo-N-methyl-L-phenylalanine (L-p-Br-MePhe), meta-iodo-N-methyl-L-phenylalanine (L-m-I-MePhe), para-iodo-N-methyl-L-phenylalanine (L-p-I-MePhe), 3-phenyl-N-methyl-L-phenylalanine, 4-phenyl-N-methyl-L-phenylalanine, 3-(4-fluorophenyl)-N-methyl-L-phenylalanine, 4-(4-fluorophenyl)-N-methyl-L-phenylalanine, 3-(4-pyridinyl)-N-methyl-L-phenylalanine, 4-(4-pyridinyl)-N-methyl-L-phenylalanine, 3-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-4-pyridinyl)-N-methyl-L-phenylalanine, 3-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 3-[4-(piperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(piperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine, 3-[4-(4-methylpiperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(4-methylpiperazin-1-yl)phen-1-

yl]phenyl-N-methyl-L-phenylalanine, β -oxo-N-methyl-L-phenylalanine (L- β -oxo-MePhe), β -acetoxy-N-methyl-L-phenylalanine (L- β -AcO-MePhe), N-methyl-L-tyrosine (L-MeTyr), O-methyl-N-methyl-L-tyrosine [L-MeTyr(Me)], N-methyl-L-alanine (L-MeAla), N-methyl-L-serine (L-MeSer), N-methyl-D-phenylalanine (D-MePhe), N-methyl-D-alanine (D-MeAla), N-methyl-D-valine (D-MeVal), N-methyl-D-serine (D-MeSer) and N-methyl-L-serine (L-MeSer) residues;

A⁵ is an α -amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle), L-norvaline (L-Nva) and L-valine (L-Val) residues;

A⁶ is an α -amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), N-methyl-L-allo-isoleucine (L-MeAlle) and L-valine (L-Val) residues;

A⁷ is an α -amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and

A⁸ is an α -amino acid residue selected from the group consisting of β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal), γ -hydroxy-N-methyl-L-valine (L- γ -OH-MeVal), N-methyl-L-valine (L-MeVal), L-valine (L-Val), N-methyl-2,3-didehydro-L-valine (L-MeDH_{2,3}Val), N-methyl-3,4-didehydro-L-valine (L-MeDH_{3,4}Val), N-methyl-L-phenylalanine (L-MePhe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), N-methyl-L-threonine (L-MeThr), sarcosine (Sar) and N, β -dimethyl-L-aspartic acid (L-N, β -MeAsp) residues.

The compound of formula (I) is selected from a compound 1.001 to 1.035 listed in Table A (below) or a compound 2.001 to 2.045 listed in Table B (below).

The following lists provides definitions, including preferred definitions, for substituents R¹, A¹, A², A³, A⁴, A⁵, A⁶, A⁷ and A⁸ with reference to the compounds of formula (I). For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document.

Table A: This table discloses 35 compounds of formula (I), wherein R¹, A¹, A², A³, A⁴, A⁵, A⁶, A⁷ and A⁸ are as set forth in Table A below:

Table A

No.	R ¹	A ¹	A ²	A ³	A ⁴	A ⁵	A ⁶	A ⁷	A ⁸
1.001	Me	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L- β -OH-MeVal
1.002	Me	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeVal
1.003	Me	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Val	L-MeVal	L-Leu	L-MeVal
1.004	Me	L-MeVal	L-Phe	L- β -OH-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeVal

1.005	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.006	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Val	L-MeVal	L-Leu	L-β-OH-MeVal
1.007	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-γ-OH-MeVal
1.008	Et	L-MeVal	L-Phe	L-β-OH-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.009	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-Val	L-Leu	L-β-OH-MeVal
1.010	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeVal
1.011	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-Val
1.012	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Leu	L-MeVal	L-Leu	L-β-OH-MeVal
1.013	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-N,β-MeAsp
1.014	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Val	L-MeVal	L-Leu	L-MeVal
1.015	Et	L-MeVal	L-Phe	L-Phe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeVal
1.016	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeDH _{3,4} Val
1.017	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MePhe
1.018	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-Val	L-Leu	L-MeVal
1.019	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MePhe
1.020	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeDH _{2,3} Val
1.021	Et	L-MeVal	L-o-FPhe	L-o-F-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.022	Et	L-MeVal	L-m-FPhe	L-m-F-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.023	Et	L-MeVal	L-Tyr	L-MeTyr	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.024	Et	L-MeVal	L-Phe	L-MePhe	L-4Hyp	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.025	Et	L-MeVal	L-Phe	L-MePhe	L-SPro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal

1.026	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Nle	L-MeVal	L-Leu	L-β-OH-MeVal
1.027	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Nva	L-β-OH-MeVal
1.028	Et	L-MeVal	L-Phe	L-MeSer	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.029	Et	L-MeVal	L-Phe	L-β-oxo-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.030	Et	L-MeVal	L-Phe	L-β-AcO-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.031	Et	L-MeVal	L-Phe	L-MeTyr	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal
1.032	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeLeu	L-Leu	L-β-OH-MeVal
1.033	Et	L-MeVal	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Alle	L-β-OH-MeVal
1.034	Et	L-MeVal	L-Phe	L-β-OH-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-MeVal
1.035	Et	L-Val	L-Phe	L-MePhe	L-Pro	L-Alle	L-MeVal	L-Leu	L-β-OH-MeVal

Table B: This table discloses 45 compounds of formula (I), wherein R¹ is ethyl, A¹ is L-MeVal, A⁴ is L-Pro, A⁶ is L-MeVal and A⁷ is L-Leu and A², A³, A⁵ and A⁸ are as set forth in Table B below:


5 Table B

No.	A ²	A ³	A ⁵	A ⁸
2.001	L-Phe	L-MeSer	L-Alle	L-β-OH-MeVal
2.002	L-Phe	L-β-AcO-MePhe	L-Alle	L-β-OH-MeVal
2.003	L-Phe	L-MeAla	L-Alle	L-β-OH-MeVal
2.004	L-Phe	D-MePhe	L-Alle	L-β-OH-MeVal
2.005	L-Phe	D-MeAla	L-Alle	L-β-OH-MeVal
2.006	L-Phe	L-MePhe	L-Alle	L-MeDH _{2,3} Val
2.007	L-Phe	D-MeVal	L-Alle	L-β-OH-MeVal
2.008	L-Cha	D-MeAla	L-Alle	L-β-OH-MeVal
2.009	L-Tyr	D-MeAla	L-Alle	L-β-OH-MeVal
2.010	L-Tyr(Ac)	D-MeAla	L-Alle	L-β-OH-MeVal

2.011	L-Tyr(<i>n</i> -hexanoyl)	D-MeAla	L-Alle	L-β-OH-MeVal
2.012	L-Tyr(Bzl)	D-MeAla	L-Alle	L-β-OH-MeVal
2.013	L-Cha	D-MeVal	L-Alle	L-β-OH-MeVal
2.014	L-Cha	D-MeSer	L-Alle	L-β-OH-MeVal
2.015	L-Phe	L-MePhe	L-Alle	L-MeThr
2.016	L-Phe	L-β-OH-MePhe	L-Alle	L-β-OH-MeVal
2.017	L-Phe	L-m-I-MePhe	L-Alle	L-β-OH-MeVal
2.018	L-Phe	L-p-I-MePhe	L-Alle	L-β-OH-MeVal
2.019	L-Phe	L-p-F-MePhe	L-Alle	L-β-OH-MeVal
2.020	L-Phe	3-(4-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.021	L-Phe	4-(4-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.022	L-Phe	3-[4-(4-methylpiperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.023	L-Phe	4-[4-(4-methylpiperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.024	L-Phe	4-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.025	L-Phe	4-(4-fluorophenyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.026	L-Phe	L-MeTyr(Me)	L-Alle	L-β-OH-MeVal
2.027	L-Phe	L-MeAla	L-Alle	L-β-OH-MeVal
2.028	L-Phe	D-MePhe	L-Alle	L-β-OH-MeVal
2.029	L-Phe	D-MeIVal	L-Alle	L-β-OH-MeVal
2.030	L-Phe	L-MePhe	L-Nle	L-β-OH-MeVal
2.031	L-Phe	L-MePhe	L-Leu	L-β-OH-MeVal
2.032	L-Phe	L-MePhe	L-Nva	L-β-OH-MeVal
2.033	L-Phe	L-MePhe	D-MeAla	L-β-OH-MeVal
2.034	L-Phe	L-m-Br-MePhe	L-Alle	L-β-OH-MeVal
2.035	L-Phe	L-p-Br-MePhe	L-Alle	L-β-OH-MeVal
2.036	L-Phe	3-phenyl-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.037	L-Phe	4-phenyl-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.038	L-Phe	3-(1-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.039	L-Phe	4-(1-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.040	L-Phe	3-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.041	L-Phe	3-(4-fluorophenyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal

2.042	L-Phe	4-(2-chloro-4-pyridinyl)-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.043	L-Phe	3-[4-(piperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.044	L-Phe	4-[4-(piperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine	L-Alle	L-β-OH-MeVal
2.045	L-Cha	L-MePhe	L-Alle	L-β-OH-MeVal

In a first variant of this first embodiment of the invention, component (A) is preferably a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof, hereinafter referred to as Aureobasidin A:




5

As used herein, the term "Aureobasidin A" represents a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof consisting, in sequence, of units derived from 2(R)-hydroxy-3(R)-methylpentanoic acid ((2R,3R)-Hmp), N-methyl-L-valine (L-MeVal), L-phenylalanine (L-Phe), N-methyl-L-phenylalanine (L-MePhe), L-proline (L-Pro), L-allo-isoleucine (L-Alle), N-methyl-L-valine (L-MeVal), L-leucine (L-Leu) and β-hydroxy-N-methyl-L-valine (L-β-OH-MeVal).

10


Component (A) may further comprise a cyclic depsipeptide of formula (I-A2) or a stereoisomer thereof, hereinafter referred to as Aureobasidin E:



(I-A2)

As used herein, the term “Aureobasidin E” represents a cyclic depsipeptide of formula (I-A2) or a stereoisomer thereof consisting, in sequence, of units derived from 2(R)-hydroxy-3(R)-methylpentanoic acid ((2R,3R)-Hmp), N-methyl-L-valine (L-MeVal), L-phenylalanine (L-Phe), β-hydroxy-N-methyl-L-phenylalanine (L-β-OH-MePhe), L-proline (L-Pro), L-allo-isoleucine (L-Alle), N-methyl-L-valine (L-MeVal), L-leucine (L-Leu) and β-hydroxy-N-methyl-L-valine (L-β-OH-MeVal).

Component (A) may further comprise a cyclic depsipeptide of formula (I-A3) or a stereoisomer thereof, hereinafter referred to as Aureobasidin G:



(I-A3)

As used herein, the term “Aureobasidin G” represents a cyclic depsipeptide of formula (I-A3) or a stereoisomer thereof consisting, in sequence, of units derived from 2(R)-hydroxy-3(R)-methylpentanoic acid ((2R,3R)-Hmp), N-methyl-L-valine (L-MeVal), L-phenylalanine (L-Phe), N-methyl-L-phenylalanine (L-MePhe), L-proline (L-Pro), L-allo-isoleucine (L-Alle), N-methyl-L-valine (L-MeVal), L-leucine (L-Leu) and N-methyl-L-valine (L-MeVal).

Component (A) may further comprise two or more cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above.

In a first variant of this embodiment of the invention, component (A) comprises Aureobasidin A and one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above.

5 Component (A) may further comprise Aureobasidin E and one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above.

10 In a preferred embodiment according to the invention, component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I) or stereoisomers thereof selected from the group consisting of compounds 1.001 to 1.004 and 1.006 to 1.035 as set forth in Table A. Preferably, component (A) comprises Aureobasidin A and at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G.

15 In an embodiment according to the invention, component (A) comprises Aureobasidin A and Aureobasidin E. In another embodiment according to the invention, component (A) comprises Aureobasidin A and Aureobasidin G. In another embodiment according to the invention, component (A) comprises Aureobasidin A, Aureobasidin E and Aureobasidin G.

In another preferred embodiment according to the invention, component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I) or stereoisomers thereof selected from the group consisting of compounds 2.001 to 2.045 as set forth in Table B.

20 In embodiments where component (A) comprises Aureobasidin A and one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof, said component (A) typically comprises:

from 10% to 99.9% by weight, preferably from 20% to 99.9% by weight, more preferably from 40% to 99.9% by weight of Aureobasidin A, and

from 0.1% to 90% by weight, preferably from 0.1% to 80% by weight, more preferably from 0.1% to 60% by weight of one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof.

25 In embodiments where component (A) comprises Aureobasidin E and one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof, said component (A) typically comprises:

from 10% to 99.9% by weight, preferably from 20% to 99.9% by weight, more preferably from 40% to 99.9% by weight of Aureobasidin E, and

30 from 0.1% to 90% by weight, preferably from 0.1% to 80% by weight, more preferably from 0.1% to 60% by weight of one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof.

In an embodiment according to the invention, component (A) typically comprises:

from 60% to 99.5% by weight of Aureobasidin A,


from 0.05% to 5% by weight of Aureobasidin E,

optionally, from 0.1% to 30% by weight of Aureobasidin G, and

35 optionally, from 0.1% to 10% by weight of one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof.

In a second embodiment of the invention, component (A) further comprises one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof.

15



wherein

R¹ is methyl or ethyl;

X⁴ is S, methylene or hydroxymethylene;


5 A⁵ is an α -amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle) and L-valine (L-Val) residues;

A⁶ is an α -amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), L-allo-isoleucine (L-Alle) and N-methyl-L-allo-isoleucine (L-MeAlle) residues;

10 A⁷ is an α -amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and

A⁸ is an α -amino acid residue selected from the group consisting of β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal), γ -hydroxy-N-methyl-L-valine (L- γ -OH-MeVal), N-methyl-L-valine (L-MeVal), N-methyl-2,3-didehydro-L-valine (L-MeDH_{2,3}Val), N-methyl-3,4-didehydro-L-valine (L-MeDH_{3,4}Val), N-methyl-L-phenylalanine (L-MePhe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), N-methyl-L-threonine (L-MeThr), sarcosine (Sar) and N, β -dimethyl-L-aspartic acid (L-N, β -MeAsp) residues.


As used herein, the term "persephanine residue" represents an α -amino acid residue of formula:



For instance component (A) further comprises a cyclic depsipeptide of formula (I-B1) or a stereoisomer thereof, hereinafter referred to as Persephacin A:

20


16



(I-B1)

As used herein, the term “Persephacin A” represents a cyclic depsipeptide of formula (I-B1) or a stereoisomer thereof consisting, in sequence, of units derived from 2(R)-hydroxy-3(R)-methylpentanoic acid ((2R,3R)-Hmp), N-methyl-L-valine (L-MeVal), L-persephanine, sarcosine (Sar), L-proline (L-Pro), L-allo-isoleucine (L-Alle), N-methyl-L-valine (L-MeVal), L-leucine (L-Leu) and β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal).


Component (A) may further comprise a cyclic depsipeptide of formula (I-B2) or a stereoisomer thereof, hereinafter referred to as Persephacin B:



(I-B2)

As used herein, the term "Persephacin B" represents a cyclic depsipeptide of formula (I-B2) or a stereoisomer thereof consisting, in sequence, of units derived from 2(R)-hydroxy-3(R)-methylpentanoic acid ((2R,3R)-Hmp), N-methyl-L-valine (L-MeVal), L-persephanine, sarcosine (Sar), L-proline (L-Pro), L-allo-isoleucine (L-Alle), L-allo-isoleucine (L-Alle), L-leucine (L-Leu) and β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal).

Component (A) may further comprise a cyclic depsipeptide of formula (I-B3) or a stereoisomer thereof, hereinafter referred to as Persephacin C:



As used herein, the term "Persephacin C" represents a cyclic depsipeptide of formula (I-B3) or a stereoisomer thereof consisting, in sequence, of units derived from 2(R)-hydroxy-3(R)-methylpentanoic acid ((2R,3R)-Hmp), N-methyl-L-valine (L-MeVal), L-persephanine, sarcosine (Sar), L-proline (L-Pro), L-allo-isoleucine (L-Alle), N-methyl-L-valine (L-MeVal), L-leucine (L-Leu) and N-methyl-L-valine (L-MeVal).

Disclosed herein is component (A) which further comprises two or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above.

Further disclosed herein is component (A) which further comprises Persephacin A and one or more other cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above.

In an another embodiment according to the invention, component (A) comprises a cyclic depsipeptides of formula (I-A1) or stereoisomers thereof and one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above.

In a variant of this embodiment of the invention, component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above.

In another variant of this embodiment of the invention, component (A) comprises Aureobasidin A, one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above, and one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above.

5 In another variant of this embodiment of the invention, component (A) comprises Aureobasidin A, at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G, and one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above.

10 Disclosed herein is a component (A) which further comprises a strain of *Aureobasidium pullulans*, generally a strain of *Aureobasidium pullulans* R106 deposited to the International Patent Organisms Depositary under accession number FERM BP-1938 or a strain of *Aureobasidium pullulans* deposited to the China General Microbiological Culture Collection Center under accession number CGMCC No. 20887.

15 It is understood, without this limiting the scope of the invention, that one or more cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above can be obtained from a fermentation broth of a strain of *Aureobasidium pullulans*, generally a strain of *Aureobasidium pullulans* R106 deposited to the International Patent Organisms Depositary under accession number FERM BP-1938 or a strain of *Aureobasidium pullulans* deposited to the China General Microbiological Culture Collection Center under accession number CGMCC No. 20887.

20 In another embodiment according to the invention, component (A) further comprises a strain or a genetically modified strain of *Sphaceloma coryli*.

It is understood, without this limiting the scope of the invention, that one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof as defined above can be obtained from a fermentation broth of a strain or a genetically modified strain of *Sphaceloma coryli*.

25 As used herein, the term "fermentation broth" refers to a composition obtained from a process of fermentation of a strain.

In another embodiment according to the invention, component (A) comprises a fermentation broth comprising two or more cyclic depsipeptides of formula (I) or stereoisomers thereof as defined above.

30 In a first variant of this embodiment of the invention, component (A) comprises a fermentation broth comprising two or more cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above.

In an embodiment according to the invention, component (A) comprises a fermentation broth comprising Aureobasidin A and one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above.

35 In another embodiment according to the invention, component (A) further comprises a fermentation broth comprising Aureobasidin E and one or more other cyclic depsipeptides of formula (I-A) or stereoisomers thereof as defined above.

The component (B) compounds are known and are commercially available and/or can be prepared using procedures known in the art and/or procedures reported in the literature.



The presence of one or more possible asymmetric carbon atoms in component (B) means that the compounds may occur in optically isomeric forms, i.e., enantiomeric or diastereomeric forms. Also, atropisomers may occur as a result of restricted rotation about a single bond. The present invention includes all those possible isomeric forms (e.g. geometric isomers) and mixtures thereof for component (B). The present invention includes all possible tautomeric forms for component (B), and also a racemic compound, i.e., a mixture of at least two enantiomers in a ratio of substantially 50:50.








In each case, the components (B) according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form.







N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book "Heterocyclic N-oxides" by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.









Component (B) comprises a compound selected from compounds B.01, B.02, B.03, B.04, B.05, B.06, B.07, B.08, B.09, B.10, B.11, B.12, B.13, B.14, B.15, B.16, B.17, B.18, B.19, B.20, B.21, B.22, B.23, B.24 or B.25 as defined in the Table C below. More preferably, component (B) is a compound selected from compounds B.01, B.02, B.03, B.04, B.05, B.06, B.07 or B.08 as defined in the Table C below. Even more preferably, component (B) is a compound selected from compounds B.01, B.02, B.03, B.04, B.05, B.06 or B.07 as defined in the Table C below.



Table C

Compound number	Compound structure	IUPAC name
B.01		ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate
B.02		N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide

B.03		N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide
B.04		N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide
B.05		1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea
B.06		1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea
B.07		3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea
B.08		N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide
B.09		4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one

B.10		5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one
B.11		N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine
B.12		(3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone
B.13		(5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone
B.14		2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide
B.15		ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate

B.16		N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
B.17		N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
B.18		N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide
B.19		N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
B.20		N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
B.21		N-[(E)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
B.22		N-[(Z)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
B.23		4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoic acid

B.24		ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazole-4-carboxylate
B.25		ethyl 1-[[4-[[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carboxylate

The presence of an asymmetric carbon atom in any of the compounds B.01, B.02, B.03, B.04, B.05, B.06, B.07, B.08, B.09, B.10, B.11, B.12, B.13, B.14, B.15, B.16, B.17, B.18, B.19, B.20, B.21, B.22, B.23, B.24 or B.25 as defined in the Table C above means that these compounds may occur in chiral enantiomeric forms, i.e., (R)- and (S)-enantiomers.

Enantiomerically pure final compounds may be obtained from racemic starting materials as appropriate via standard physical separation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, e.g., by using chiral starting materials.

In a preferred composition according to the invention, component (A) comprises one or more cyclic depsipeptides of formula (I-A1) or stereoisomers thereof as defined above, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.

In another preferred composition according to the invention, component (A) is Aureobasidin A, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 50:1 to 1:200.

In another preferred composition according to the invention, component (A) is Aureobasidin A,
5 and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 50:1 to 1:20.

In another preferred composition according to the invention, component (A) is Aureobasidin A,
15 and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 30:1 to 1:1.

In another preferred composition according to the invention, component (A) is Aureobasidin A,
and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 10:1 to 3:1.

In another preferred composition according to the invention, component (A) is Aureobasidin E,
and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 10:1 to 3:1.

yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 50:1 to 1:200.

In another preferred composition according to the invention, component (A) is Aureobasidin E,
5 and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 50:1 to 1:20.

In another preferred composition according to the invention, component (A) is Aureobasidin E,
15 and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 30:1 to 1:1.

In another preferred composition according to the invention, component (A) is Aureobasidin E,
and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 10:1 to 3:1.

In another preferred composition according to the invention, component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I) or stereoisomers thereof selected from the group consisting of compounds 1.001 to 1.004 and 1.006 to 1.035 as set forth in Table A,
35 preferably component (A) comprises Aureobasidin A and at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 50:1 to 1:200.

In a composition disclosed herein component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I) or stereoisomers thereof selected from the group consisting of compounds 1.001 to 1.004 and 1.006 to 1.035 as set forth in Table A, preferably component (A) comprises Aureobasidin A and at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 50:1 to 1:20.

In a composition disclosed herein, component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I) or stereoisomers thereof selected from the group consisting of compounds 1.001 to 1.004 and 1.006 to 1.035 as set forth in Table A, preferably component (A) comprises Aureobasidin A and at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 30:1 to 1:1.

In a composition disclosed herein, component (A) comprises Aureobasidin A and one or more cyclic depsipeptides of formula (I) or stereoisomers thereof selected from the group consisting of compounds 1.001 to 1.004 and 1.006 to 1.035 as set forth in Table A, preferably component (A) comprises Aureobasidin A and at least one other cyclic depsipeptide of formula (I-A) or a stereoisomer thereof selected from the group consisting of Aureobasidin E and Aureobasidin G, and component (B)

is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 10:1 to 3:1.

The composition disclosed herein may further comprises a strain of *Aureobasidium pullulans*, generally a strain of *Aureobasidium pullulans* R106, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.

The composition disclosed herein may further , comprise a fermentation broth comprising a cyclic depsipeptides of formula (I-A1) or stereoisomers thereof as defined above, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.

In another preferred composition according to the invention, component (A) is a fermentation broth comprising Aureobasidin A or stereoisomers thereof as defined above, and component (B) is a compound selected from the group consisting of ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl]phenyl)methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl)methyl]urea, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.

The compositions disclosed herein may in certain circumstances comprise an additional active ingredient component (C), which is different to component (B), wherein component (C) is selected from the list of components (B) as defined according to the invention.

Where the compositions comprise a component (A), a component (B) and a component (C), the weight ratio of component (A) to the sum of component (B) and component (C) may be from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.

The weight ratio of component (A) to the sum of component (B) and component (C) may be of 1:1, or 1:2, or 1:4, or 1:8, or 2:1, or 4:1, or 8:1, or 16:1, or 20:1, or 1:200, or 1:100, or 1:50, or 1:25, or 1:20, or 1:12.5, or 1:10, or 1:6.2, or 1:5, or 1:2.5, or 2:1, or 3:1, or 10:1, or 20:1, or 30:1.

The compounds of formula (I) or stereoisomers thereof can be prepared by methods known to the person skilled in the art. The compounds of formula (I) can be either purchased or prepared using synthetic or semi-synthetic chemistry or fermentation processes. For example, the compounds of formula (I-A) or stereoisomers thereof can be prepared by methods known in Takesako et al., *The Journal of Antibiotics*, 1991, 44, 919-924, Takesako et al., *Tetrahedron*, 1996, 52, 4327-4346 and Maharani et al. *Tetrahedron*, 2014, 70, 2351-2358. A fermentation broth comprising one or more compounds of formula (I-A) or stereoisomers thereof can be obtained from a process of fermentation of a strain of *Aureobasidium pullulans*, generally by a strain of *Aureobasidium pullulans* R106. A

fermentation broth comprising one or more compounds of formula (I-B) or stereoisomers thereof can be obtained from a process of fermentation of a strain of *Sphaceloma coryli*. The fermentation broth may not require purification. Alternatively, one or more compounds of formula (I) can be isolated from the fermentation broth and purified, e.g. by chromatography using a sorbent (e.g., silica and reverse phase silica gels, optically active sorbents, resins) or one or more solvents (e.g., partitioning, counter current separation, mixture of polyphasic solvents) or other chemical means (e.g., crystallization, recrystallization, salt formation, and precipitation) to achieve the final degree of purity. Purity of the compounds of formula (I) or stereoisomers thereof can include, but is not limited to, a range of from 10% to 20%, or from 20% to 30%, or from 30% to 40%, or from 40% to 50%, or from 50% to 60%, or from 60% to 70%, or from 70% to 80%, or from 80% to 90%, or from 90% to 100%. The purity of the compounds of formula (I) or stereoisomers thereof can be measured by any technique known to the person skilled in the art, including NMR, mass spectrometry, liquid chromatography-mass spectrometry (LCMS), high performance liquid chromatography (HPLC) and other analytical means.

The term "fungicide" as used herein means a compound that controls, modifies, or prevents the growth of fungi. The term "fungicidally effective amount" means the quantity of such a compound or combination of such compounds that is capable of producing an effect on the growth of fungi.

Controlling or modifying effects include all deviation from natural development, such as killing, retardation and the like, and prevention includes barrier or other defensive formation in or on a plant to prevent fungal infection.

The term "plants" refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, and fruits.

The term "plant propagation material" denotes all generative parts of a plant, for example seeds or vegetative parts of plants such as cuttings and tubers. It includes seeds in the strict sense, as well as roots, fruits, tubers, bulbs, rhizomes, and parts of plants.

The term "locus" as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation.

Throughout this document the expression "composition" stands for the various mixtures or combinations of components (A) and (B) (including the above-defined embodiments), for example in a single "ready-mix" form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a "tank-mix", and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the components (A) and (B) is not essential for working the present invention.

The composition according to the invention is effective against harmful microorganisms, such as microorganisms, that cause phytopathogenic diseases, in particular against phytopathogenic fungi and bacteria.

The composition of the invention may be used to control plant diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and/or Deuteromycete, Blasocladiomycete, Chytridiomycete, Glomeromycete and/or Mucoromycete classes:

Oomycetes, including Phytophthora diseases such as those caused by *Phytophthora capsici*, *Phytophthora infestans*, *Phytophthora sojae*, *Phytophthora fragariae*, *Phytophthora nicotianae*, *Phytophthora cinnamomi*, *Phytophthora citricola*, *Phytophthora citrophthora* and *Phytophthora erythroseptica*; Pythium diseases such as those caused by *Pythium aphanidermatum*, *Pythium arrhenomanes*, *Pythium graminicola*, *Pythium irregulare* and *Pythium ultimum*; diseases caused by Peronosporales such as *Peronospora destructor*, *Peronospora parasitica*, *Peronospora manshurica*, *Peronospora tabacina*, *Plasmopara viticola*, *Plasmopara halstedii*, *Pseudoperonospora cubensis*, *Albugo candida*, *Sclerophthora macrospora* and *Bremia lactucae*; and others such as *Aphanomyces cochlioides*, *Labyrinthula zosterae*, *Peronosclerospora sorghi* and *Sclerospora graminicola*;

Ascomycetes, including blotch, spot, blast or blight diseases and/or rots for example those caused by Pleosporales such as *Stemphylium solani*, *Stagonospora tainanensis*, *Spilocaea oleaginea*,

- Setosphaeria turcica*, *Pyrenochaeta lycoperisici*, *Pleospora herbarum*, *Phoma destructiva*, *Phaeosphaeria herpotrichoides*, *Phaeocryptococcus gaeumannii*, *Ophiosphaerella graminicola*, *Ophiobolus graminis*, *Leptosphaeria maculans*, *Hendersonia creberrima*, *Helminthosporium tritici-repentis*, *Drechslera glycines*, *Didymella bryoniae*, *Cycloconium oleagineum*, *Corynespora*
- 5 *cassiicola*, *Cochliobolus sativus*, *Bipolaris cactivora*, *Venturia inaequalis*, *Pyrenophora teres*, *Pyrenophora tritici-repentis*, *Alternaria alternata*, *Alternaria brassicicola*, *Alternaria solani* and *Alternaria tomatophila*, Capnodiales such as *Septoria tritici*, *Septoria nodorum*, *Septoria glycines*, *Cercospora arachidicola*, *Cercospora beticola*, *Cercospora sojae*, *Cercospora zeae-maydis*, *Cercospora capsellae* and *Cercospora herpotrichoides*, *Cladosporium carpophilum*, *Cladosporium*
- 10 *effusum*, *Passalora fulva*, *Cladosporium oxysporum*, *Dothistroma septosporum*, *Isariopsis clavispora*, *Mycosphaerella fijiensis*, *Mycosphaerella graminicola*, *Mycovellosiella koepkei*, *Phaeoisariopsis bataticola*, *Pseudocercospora vitis*, *Pseudocercospora herpotrichoides*, *Ramularia beticola*, *Ramularia collo-cygni*, Magnaporthales such as *Gaeumannomyces graminis*, *Magnaporthe grisea*, *Magnaporthe oryzae*, Diaporthales such as *Anisogramma anomala*, *Apiognomonina errabunda*,
- 15 *Cytospora platani*, *Diaporthe phaseolorum*, *Discula destructiva*, *Gnomonia fructicola*, *Greeneria uvicola*, *Melanconium juglandinum*, *Phomopsis viticola*, *Sirococcus clavigignenti-juglandacearum*, *Tubakia dryina*, *Dicarpella* spp., *Valsa ceratosperma*, and others such as *Actinothyrium graminis*, *Ascochyta pisi*, *Aspergillus flavus*, *Aspergillus fumigatus*, *Aspergillus nidulans*, *Asperisporium caricae*, *Blumeriella jaapii*, *Candida* spp., *Capnodium ramosum*, *Cephaloascus* spp., *Cephalosporium*
- 20 *gramineum*, *Ceratocystis paradoxa*, *Chaetomium* spp., *Hymenoscyphus pseudoalbidus*, *Coccidioides* spp., *Cylindrosporium padi*, *Diplocarpon malae*, *Drepanopeziza campestris*, *Elsinoe ampelina*, *Epicoccum nigrum*, *Epidermophyton* spp., *Eutypa lata*, *Geotrichum candidum*, *Gibellina cerealis*, *Gloeocercospora sorghi*, *Gloeodes pomigena*, *Gloeosporium perennans*; *Gloeotinia temulenta*, *Griphosphaeria corticola*, *Kabatiella lini*, *Leptographium microsporum*, *Leptosphaerulina crassiasca*,
- 25 *Lophodermium seditiosum*, *Marssonina graminicola*, *Microdochium nivale*, *Monilinia fructicola*, *Monilinia laxa*, *Monilinia fructigena*, *Monographella albescens*, *Monosporascus cannonballus*, *Naemacystus* spp., *Ophiostoma novo-ulmi*, *Paracoccidioides brasiliensis*, *Penicillium expansum*, *Pestalotia rhododendri*, *Petriellidium* spp., *Pezicula* spp., *Phialophora gregata*, *Phialophora tetraspora*, *Phyllachora pomigena*, *Phymatotrichum omnivora*, *Physalospora abdita*, *Plectosporium tabacinum*,
- 30 *Polyscytalum pustulans*, *Pseudopeziza medicaginis*, *Pyrenopeziza brassicae*, *Ramulispora sorghi*, *Rhabdocline pseudotsugae*, *Rhynchosporium secalis*, *Sacrocladium oryzae*, *Scedosporium* spp., *Schizothyrium pomi*, *Sclerotinia sclerotiorum*, *Sclerotinia minor*, *Sclerotium* spp., *Typhula ishikariensis*, *Seimatosporium mariae*, *Lepteutypa cupressi*, *Septocysta ruborum*, *Sphaceloma perseae*, *Sporonema phacidiioides*, *Stigmata palmivora*, *Tapesia yallundae*, *Taphrina bullata*, *Thielaviopsis basicola*,
- 35 *Trichoseptoria fructigena*, *Zygophiala jamaicensis*; powdery mildew diseases for example those caused by Erysiphales such as *Blumeria graminis*, *Erysiphe polygoni*, *Uncinula necator*, *Sphaerotheca fuliginea*, *Podosphaera leucotricha*, *Podosphaera macularis*, *Podosphaera pannosa*, *Golovinomyces cichoracearum*, *Leveillula taurica*, *Microsphaera diffusa*, *Oidiopsis gossypii*, *Phyllactinia guttata* and

Oidium arachidis; molds for example those caused by Botryosphaerales such as *Dothiorella aromatica*, *Diplodia seriata*, *Guignardia bidwellii*, *Botrytis cinerea*, *Botrytis tracheiphila*, *Botryotinia allii*, *Botryotinia fabae*, *Fusicoccum amygdali*, *Lasiodiplodia theobromae*, *Macrophoma theicola*, *Macrophomina phaseolina*, *Phyllosticta cucurbitacearum*; anthracnoses for example those caused by

5 Glomerelales such as *Colletotrichum gloeosporioides*, *Colletotrichum lagenarium*, *Colletotrichum gossypii*, *Glomerella cingulata*, and *Colletotrichum graminicola*; and wilts or blights for example those caused by Hypocreales such as *Acremonium strictum*, *Claviceps purpurea*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium brasiliense*, *Fusarium tucumaniae*, *Fusarium cuneirostrum*, *Fusarium virguliforme*, *Fusarium oxysporum*, *Fusarium subglutinans*, *Fusarium oxysporum* f.sp.

10 *cubense*, *Gerlachia nivale*, *Gibberella fujikuroi*, *Gibberella zeae*, *Gliocladium* spp., *Myrothecium verrucaria*, *Nectria ramulariae*, *Trichoderma viride*, *Trichothecium roseum*, and *Verticillium theobromae*;

Basidiomycetes, including smuts for example those caused by Ustilaginales such as *Ustilaginoidea virens*, *Ustilago nuda*, *Ustilago tritici*, *Ustilago zeae*, rusts for example those caused by

15 Pucciniales such as *Cerotelium fici*, *Chrysomyxa arctostaphyli*, *Coleosporium ipomoeae*, *Hemileia vastatrix*, *Puccinia arachidis*, *Puccinia cacabata*, *Puccinia graminis*, *Puccinia recondita*, *Puccinia sorghi*, *Puccinia hordei*, *Puccinia striiformis* f.sp. *hordei*, *Puccinia striiformis* f.sp. *secalis*, *Pucciniastrum coryli*, or Uredinales such as *Cronartium ribicola*, *Gymnosporangium juniperi-viginianae*, *Melampsora medusae*, *Phakopsora pachyrhizi*, *Phakopsora meibomiae*, *Phragmidium mucronatum*, *Physopella ampelosisidis*, *Tranzschelia discolor* and *Uromyces viciae-fabae*; and other

20 rots and diseases such as those caused by *Cryptococcus* spp., *Exobasidium vexans*, *Marasmiellus inoderma*, *Mycena* spp., *Sphacelotheca reiliana*, *Typhula ishikariensis*, *Urocystis agropyri*, *Itersonilia haperplexans*, *Corticium invisum*, *Laetisaria fuciformis*, *Waitea circinata*, *Rhizoctonia solani*, *Thanetophorus cucurmeris*, *Entyloma dahliae*, *Entylomella microspora*, *Neovossia molinae* and

25 *Tilletia caries*;

Blastocladiomycetes, such as *Physoderma maydis*; and

Mucoromycetes, such as *Choanephora cucurbitarum*; *Mucor* spp.; *Rhizopus arrhizus*, *Rhizopus oryzae*, *Rhizopus stolonifera*, *Rhizopus nigricans*, as well as diseases caused by other species and genera closely related to those listed above.

30 In addition to their fungicidal activity, the compositions may also have activity against bacteria such as *Erwinia amylovora*, *Erwinia caratovora*, *Xanthomonas campestris*, *Pseudomonas syringae*, *Streptomyces scabies* and other related species as well as certain protozoa.

The compositions according to the invention are particularly effective against phytopathogenic fungi belonging to the following classes: Ascomycetes (e.g. *Venturia*, *Alternaria*, *Podosphaera*, *Erysiphe*, *Magnaporthe*, *Monilinia*, *Mycosphaerella*, *Uncinula*); Basidiomycetes (e.g. the genus *Hemileia*, *Rhizoctonia*, *Phakopsora*, *Puccinia*, *Ustilago*, *Tilletia*); Fungi imperfecti (also known as Deuteromycetes; e.g. *Botrytis*, *Colletotrichum*, *Helminthosporium*, *Rhynchosporium*, *Fusarium*, *Septoria*, *Cercospora*, *Alternaria*, *Penicillium*, *Pyricularia* and *Pseudocercospora*); Oomycetes (e.g.

35

Phytophthora, *Peronospora*, *Pseudoperonospora*, *Albugo*, *Bremia*, *Pythium*, *Pseudosclerospora*, *Plasmopara*).

Preferably, the compositions according to the invention may be effective against phytopathogenic fungi selected from the group consisting of *Alternaria*, *Ascochyta*, *Botrytis*,

- 5 *Cercospora*, *Cochliobolus sativus*, *Colletotrichum*, *Colletotrichum lagenarium*, *Corynespora*, *Erysiphe*, *Erysiphe cichoracearum*, *Sphaerotheca fuliginea*, *Fusarium*, *Fusarium oxysporum*, *Gäumannomyces graminis*, *Guignardia*, *Helminthosporium*, *Hemileia vastatrix*, *Magnaporthe*, *Magnaporthe oryzae*, *Monilinia*, *Mycosphaerella*, *Mycosphaerella arachidis*, *Phakopsora*, *Phoma*, *Phomopsis*, *Puccinia*, *Pseudocercospora*, *Pseudopezicula*, *Phragmidium mucronatum*, *Podosphaera*, *Pyrenophora*,
10 *Pyrenophora teres*, *Pyricularia*, *Pyricularia oryzae*, *Ramularia*, *Ramularia collo-cygni*, *Rhizoctonia*, *Rhizoctonia solani*, *Rhynchosporium secalis*, *Sclerotinia*, *Septoria*, *Septoria tritici*, *Sphacelotheca reilliana*, *Tilletia*, *Urocystis occulta*, *Ucinula*, *Ustilago*, *Venturia*, *Monilia*, and *Penicillium*.

The compositions of the present invention may be particularly effective against phytopathogenic fungi selected from the group consisting of *Alternaria*, *Botrytis*, *Cercospora*, *Colletotrichum*,
15 *Corynespora*, *Guignardia*, *Mycosphaerella*, *Monilinia*, *Penicillium*, *Phakopsora*, *Phomopsis*, *Podosphaera*, *Pseudopezicula*, *Septoria*, *Ucinula* and *Venturia*.

The compositions of the present invention may be effective especially against phytopathogenic fungi selected from the group consisting of *Alternaria solani*, *Alternaria alternata*, *Alternaria porri*, *Botrytis cinerea*, *Botrytis allii*, *Botrytis squamosa*, *Cercospora capsici*, *Colletotrichum lagenarium*,
20 *Corynespora cassicola*, *Guignardia bidwellii*, *Monilinia fructicola*, *Monilinia fructigena*, *Monilinia laxa*, *Penicillium digitatum*, *Penicillium italicum*, *Penicillium expansum*, *Phomopsis viticola*, *Podosphaera leucotricha*, *Podosphaera xanthii*, *Pseudopezicula tracheiphila*, *Septoria tritici*, *Ucinula necator* and *Venturia inaequalis*.

According to the invention "useful plants" typically comprise the following perennial or annual
25 plants:

grains such as cereals, e.g. barley, maize (corn), millet, oats, rice, rye, sorghum, triticale, tritordeum and wheat, amaranth, buckwheat, chia, quinoa, and canihua;

fruits and tree nuts such as grape vine (table and wine grapes), almond, apple, apricot, avocado, banana, blackberry, blueberry, breadfruit, cacao, cashew, cherimoya, cherry, chestnut (for
30 nuts), chokeberry, citrus (including grapefruit, lime, lemon, orange, calamansi), coconut, coffee, cranberry, currant, date, feijoa fruit, fig, filbert (hazelnut), gooseberry, guava, kiwi, litchi, macadamia, mango, nectarine, olive, papaya, passion fruit, peach, pear, pecan, persimmon, pineapple, pistachio, plum (including prune), pomegranate, quince, raspberry, strawberry, suriname cherry, and walnut;

vegetables such as artichoke, asparagus, bean (snap, green, dry, edible), beet (table), broccoli/
35 broccoli raab, Brussels sprouts, cabbage (incl. Chinese), carrot, cauliflower, celeriac, celery, chickpeas, chive, collards (including kale), cucumber, edamame, eggplant, endive, pea (garden, dry, edible), garlic, horseradish, kohlrabi, leek, lentils, lettuce, melon, mushroom (cultivated), mustard and other greens, okra, onion, parsley, parsnip, pepper, potato, prickly pear, pumpkin, radish, rhubarb,

rutabaga, salsify, spinach, squash (summer and winter), sweet corn, sweet potato, Swiss chard, taro, tomato/tomatillo, turnip, and watermelon;

field crops such as sugar beet, sugarcane, tobacco, peanut, soybean;

oil seed crops such as oilseed rape (canola), mustard, camelina, crambe, sunflower, poppy,

5 sesame, and safflower;

forage crops for example alfalfa, clover, cowpea, vetches, sainfoin, lupine, fodder beet, ryegrass, kentucky bluegrass, fescue, orchard grass; fiber crops such as cotton, flax, hemp, jute and sisal;

forest plants including coniferous species e.g. larch, fir, or pine, temperate and tropical
10 hardwoods e.g. oak, birch, beech, teak, or mahogany, and tree species in arid zones, e.g. eucalyptus tree;

horticulture crops such as hops, maple (maple syrup), tea, natural rubber plants and turfgrass e.g. bentgrass, kentucky bluegrass, ryegrass, Fescues, bermudagrass, centipede grass, crested hairgrass, kikuyugrass, st. augustinegrass, zoysiagrass, dichondra, timothy grass, tufted hairgrass;

15 floriculture, greenhouse and nursery plants including flowers, broad-leaved trees or evergreens as an example begonia, dahlia, geranium, impatiens, petunia, coleus, marigold, pansy, snapdragon, african violet, azalea, florist chrysanthemum, flowering bulbs, hydrangea, lily, orchid, poinsettia, rose, astilbe, coreopsis, delphinium, dianthus, heuchera, hosta, phlox, rudbeckia, salvia, vinca, columbine, daylily, garden chrysanthemum, ivy, ornamental grasses, peony, delphinium, gladiolus, iris,
20 snapdragon, tulip, eucalyptus, pittosporum, fern, anthurium, dieffenbachia, dracaena, ficus, philodendron, spathiphyllum, bromeliad, cacti, palm, balsam fir, blue spruce, douglas fir, fraser fir, noble fir, scotch pine, white pine, magnolia, ash, elm, flowering cherry, flowering plum, hawthorn, redbud, and serviceberry;

propagative materials such as bare-root divisions, cuttings, liners, plug seedlings, seeds, tissue-
25 cultured plantlets, and prefinished plants;

culinary herbs and spices for example allspice, Angelica spp., anise, annatto, arugula, asafetida, basil (all types), bay (cultivated), bladder wrack (seaweed), Bolivian coriander, borage, calendula (herbal uses), candle nut, caper, caraway, cardamom, cassia spice, cinnamon, clary sage, cloves, catnip, chamomile, chervil, chicory, cicely, cilantro, comfrey, coriander, cress, cumin, curry, dill,
30 fennel, fenugreek, filé (cultivated), fingerroot, galangal, ginger, hops, horehound, hyssop, lavender, lemon balm, lemon thyme, lovage, mace, mahlab, malabathrum, marjoram, mint (all types), mugwort, nutmeg, oregano, orris root, paprika, parsley, pepper, rosemary, rue, saffron, sage (all types), savory (all types), sorrel, tarragon, thyme, turmeric, vanilla, wasabi, and watercress; and

medicinal herbs for example arum, Artemisia spp., astragalus, boldo, comfrey, coneflower,
35 fenugreek, feverfew, foxglove, ginkgo biloba, ginseng, goat's rue, goldenseal, gypsywort, horehound, horsetail, lavender, liquorice, marshmallow, mullein, nettle, passionflower, patchouli, pennyroyal, pokeweed, skullcap, sorrel, St. John's wort, senna, sow thistle, stevia, tansy, witch hazel, wood betony, wormwood, yarrow, yerba buena, and Ylang Ylang.

This list does not represent any limitation, however, preferably, the useful plant may be selected from the group consisting of wheat, barley, rice, soybean, apples, almonds, cherries, raspberries, grapes, cucumbers, peanuts, tomatoes, strawberries, citrus and bananas.

The term "useful plants" is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyruvyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.

The term "useful plants" is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria. Examples of toxins which can be expressed include δ -endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins of bacteria colonising nematodes, and toxins produced by scorpions, arachnids, wasps and fungi.

An example of a crop that has been modified to express the *Bacillus thuringiensis* toxin is the Bt maize KnockOut® (Syngenta Seeds). An example of a crop comprising more than one gene that codes for insecticidal resistance and thus expresses more than one toxin is VipCot® (Syngenta Seeds). Crops or seed material thereof can also be resistant to multiple types of pests (so-called stacked transgenic events when created by genetic modification). For example, a plant can have the ability to express an insecticidal protein while at the same time being herbicide tolerant, for example Herculex I® (Dow AgroSciences, Pioneer Hi-Bred International).

Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins, for example insecticidal proteins from *Bacillus cereus* or *Bacillus popilliae*; or insecticidal proteins from *Bacillus thuringiensis*, such as δ -endotoxins, e.g. CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c, or vegetative insecticidal proteins (VIP), e.g. VIP1, VIP2, VIP3 or VIP3A; or insecticidal proteins of bacteria colonising nematodes, for example *Photorhabdus* spp. or *Xenorhabdus* spp., such as *Photorhabdus luminescens*, *Xenorhabdus nematophilus*; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as *Streptomyces* toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysone

inhibitors, HMG-CoA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.

In the context of the present invention there are to be understood by δ -endotoxins, for example CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c, or vegetative insecticidal proteins (VIP), for example VIP1, VIP2, VIP3 or VIP3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701). An example for a truncated toxin is a truncated CryIA(b), which is expressed in the Bt11 maize from Syngenta Seed SAS, as described below. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of CryIIIA055, a cathepsin-D-recognition sequence is inserted into a CryIIIA toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO 93/07278, WO 95/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.

The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90/13651.

The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard® (maize variety that expresses a CryIA(b) toxin); YieldGard Rootworm® (maize variety that expresses a CryIIIB(b1) toxin); YieldGard Plus® (maize variety that expresses a CryIA(b) and a CryIIIB(b1) toxin); Starlink® (maize variety that expresses a Cry9(c) toxin); Herculex I® (maize variety that expresses a CryIF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CryIA(c) toxin); Bollgard I® (cotton variety that expresses a CryIA(c) toxin); Bollgard II® (cotton variety that expresses a CryIA(c) and a CryIIA(b) toxin); VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potato variety that expresses a CryIIIA toxin); Nature-Gard® and Protecta®.

Further examples of such transgenic crops are:

1. **Bt11 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified *Zea mays* which has been rendered resistant to attack by the European corn borer (*Ostrinia nubilalis* and *Sesamia nonagrioides*) by transgenic expression of a truncated CryIA(b) toxin. Bt11 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

2. **Bt176 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified *Zea mays* which has been rendered resistant to attack by the European corn borer (*Ostrinia nubilalis* and *Sesamia nonagrioides*) by transgenic expression of a CryIA(b) toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

3. **MIR604 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified CryIIIA toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-D-protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810.

4. **MON 863 Maize** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a CryIIIB(b1) toxin and has resistance to certain Coleoptera insects.

5. **IPC 531 Cotton** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02.

6. **1507 Maize** from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein Cry1F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.

7. **NK603 × MON 810 Maize** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 × MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from *Agrobacterium sp.* strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CryIA(b) toxin obtained from *Bacillus thuringiensis subsp. kurstaki* which brings about tolerance to certain Lepidoptera, include the European corn borer.

The term "useful plants" is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called "pathogenesis-related proteins" (PRPs, see e.g. EP-A-0 392 225). Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0 392 225, WO 95/33818, and EP-A-0 353 191. The methods of producing

such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.

Antipathogenic substances which can be expressed by such transgenic plants include, for example, ion channel blockers, such as blockers for sodium and calcium channels, for example the viral KP1, KP4 or KP6 toxins; stilbene synthases; bibenzyl synthases; chitinases; glucanases; the so-called "pathogenesis-related proteins" (PRPs; see e.g. EP-A-0 392 225); antipathogenic substances produced by microorganisms, for example peptide antibiotics or heterocyclic antibiotics (see e.g. WO 95/33818) or protein or polypeptide factors involved in plant pathogen defence (so-called "plant disease resistance genes", as described in WO 03/000906).

The compositions according to the present invention are particularly effective to control or prevent phytopathogenic diseases, especially powdery mildews, rusts, leaf spot, early blights or molds, caused by certain phytopathogenic fungi on grains, fruits and tree nuts, vegetables, field crops, oil seed crops, forage crops, forest plants, horticulture crops, floriculture, greenhouse and nursery plants, propagative materials, culinary herbs and spices, and medicinal herbs, such as:

Alternaria solani, preferably on tomatoes.

Alternaria alternata, preferably on aubergines.

Alternaria porri, preferably on onions.

Botrytis cinerea, preferably on tomatoes, peppers, onions, pomes, stone fruits, kiwi, blueberry, sugar beet or grapes.

Botrytis allii, preferably on onions.

Botrytis squamosa, preferably on onions.

Cercospora capsici, preferably on peppers.

Corynespora cassicola, preferably on tomatoes.

Guignardia bidwellii, preferably on grapes.

Monilinia fructicola, preferably on cherries, peaches, plums, prunes, nectarines or almonds.

Monilinia fructigena, preferably on cherries, peaches, plums, prunes, nectarines or almonds.

Monilinia laxa, preferably on cherries, peaches, plums, prunes, nectarines or almonds.

Phomopsis viticola, preferably on grapes.

Podosphaera leucotricha, preferably on apples.

Podosphaera xanthii, preferably on cucurbits.

Pseudopezicula tracheiphila, preferably on grapes.

Uncinula necator, preferably on grapes.

Venturia inaequalis, preferably on apples.

The compositions according to the present invention are furthermore particularly effective against seedborne and soilborne diseases, such as *Alternaria* spp., *Ascochyta* spp., *Botrytis cinerea*, *Cercospora* spp., *Claviceps purpurea*, *Cochliobolus sativus*, *Colletotrichum* spp., *Epicoccum* spp., *Fusarium graminearum*, *Fusarium moniliforme*, *Fusarium oxysporum*, *Fusarium proliferatum*, *Fusarium solani*, *Fusarium subglutinans*, *Gäumannomyces graminis*, *Helminthosporium* spp.,

Microdochium nivale, Phoma spp., Pyrenophora graminea, Pyricularia oryzae, Rhizoctonia solani, Rhizoctonia cerealis, Sclerotinia spp., Septoria spp., Sphacelotheca reilliana, Tilletia spp., Typhula incarnata, Urocystis occulta, Ustilago spp. or Verticillium spp.; in particular against pathogens of cereals, such as wheat, barley, rye or oats; maize; rice; cotton; soybean; turf; sugarbeet; oil seed rape; potatoes; pulse crops, such as peas, lentils or chickpea; and sunflower.

The compositions according to the present invention are furthermore particularly effective against post harvest diseases such as Botrytis cinerea, Colletotrichum musae, Curvularia lunata, Fusarium semitectum, Geotrichum candidum, Monilinia fructicola, Monilinia fructigena, Monilinia laxa, Mucor piriformis, Penicilium italicum, Penicilium solitum, Penicillium digitatum or Penicillium expansum in particular against pathogens of fruits, such as pomefruits, for example apples and pears, stone fruits, for example peaches and plums, citrus, melons, papaya, kiwi, mango, berries, for example strawberries, avocados, pomegranates and bananas, and nuts.

The compositions of the present invention may also be used in crop enhancement. According to the present invention, "crop enhancement" means an improvement in plant vigour, an improvement in plant quality, improved tolerance to stress factors, and/or improved input use efficiency.

According to the present invention, an "improvement in plant vigour" means that certain traits are improved qualitatively or quantitatively when compared with the same trait in a control plant which has been grown under the same conditions in the absence of the method of the invention.

According to the present invention, an "improvement in plant quality" means that certain traits are improved qualitatively or quantitatively when compared with the same trait in a control plant which has been grown under the same conditions in the absence of the method of the invention. According to the present invention, an "improved tolerance to stress factors" means that certain traits are improved qualitatively or quantitatively when compared with the same trait in a control plant which has been grown under the same conditions in the absence of the method of the invention. According to the present invention, an "improved input use efficiency" means that the plants are able to grow more effectively using given levels of inputs compared to the grown of control plants which are grown under the same conditions in the absence of the method of the invention.

Other crop enhancements of the present invention include a decrease in plant height, or reduction in tillering, which are beneficial features in crops or conditions where it is desirable to have less biomass and fewer tillers.

Some compositions according to the invention have a systemic action and can be used as foliar, soil and seed treatment fungicides.

With the compositions according to the invention it is possible to inhibit or destroy the phytopathogenic microorganisms which occur in plants or in parts of plants (fruit, blossoms, leaves, stems, tubers, roots) in different useful plants, while at the same time the parts of plants which grow later are also protected from attack by phytopathogenic microorganisms.

The compositions according to the invention can be applied to the phytopathogenic microorganisms, the useful plants, the locus thereof, the propagation material thereof, storage goods or technical materials threatened by microorganism attack.

5 The compositions according to the invention may be applied before or after infection of the useful plants, the propagation material thereof, storage goods or technical materials by the microorganisms.

The compositions comprising component (A) in combination with component (B) can be applied, for example, in a single "ready-mix" form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a "tank-mix", and in a combined use
10 of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compound of component (A) and the active ingredient of component (B) is not essential for working the present invention.

15 The compositions according to the invention are preventively and/or curatively valuable active ingredients in the field of pest control, even at low rates of application.

When applied to the useful plants, the component (A) is applied at a rate of from 25 g a.i./ha to 500 g a.i./ha in association with 10 g a.i./ha to 500 g a.i./ha of component (B). In another embodiment of the invention, when applied to the useful plants, the component (A) is applied at a rate of from 25 g a.i./ha to 500 g a.i./ha in association with 25 g a.i./ha to 500 g a.i./ha of component (B). In another
20 embodiment of the invention, when applied to the useful plants, the component (A) is applied at a rate of from 25 g a.i./ha to 250 g a.i./ha in association with 25 g a.i./ha to 250 g a.i./ha of component (B).

In a preferred embodiment of the invention, the method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, comprises applying to the useful plants, the locus thereof or propagation material
25 thereof a composition as defined according to the invention, wherein the component (A) is applied at a rate of from 25 g a.i./ha to 500 g a.i./ha in association with 10 g a.i./ha to 500 g a.i./ha of component (B).

In another embodiment of the invention, the method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation
30 material thereof, comprises applying to the useful plants, the locus thereof or propagation material thereof a composition as defined according to the invention, wherein the component (A) is applied at a rate of from 25 g a.i./ha to 500 g a.i./ha in association with 25 g a.i./ha to 500 g a.i./ha of component (B).

In another embodiment of the invention, the method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation
35 material thereof, comprises applying to the useful plants, the locus thereof or propagation material thereof a composition as defined according to the invention, wherein the component (A) is applied at a

rate of from 25 g a.i./ha to 250 g a.i./ha in association with 25 g a.i./ha to 250 g a.i./ha of component (B).

The method of controlling or preventing phytopathogenic diseases according to the invention may be particularly effective against phytopathogenic fungi selected from the group consisting of

5 *Alternaria*, *Botrytis*, *Cercospora*, *Colletotrichum*, *Corynespora*, *Guignardia*, *Mycosphaerella*, *Monilinia*, *Penicillium*, *Phakopsora*, *Phomopsis*, *Podosphaera*, *Pseudopezicula*, *Septoria*, *Uncinula* and *Venturia*.

The method of controlling or preventing phytopathogenic diseases according to the invention may be effective especially against phytopathogenic fungi selected from the group consisting of

10 *Alternaria solani*, *Alternaria alternata*, *Alternaria porri*, *Botrytis cinerea*, *Botrytis allii*, *Botrytis squamosa*, *Cercospora capsici*, *Colletotrichum lagenarium*, *Corynespora cassicola*, *Guignardia bidwellii*, *Monilinia fructicola*, *Monilinia fructigena*, *Monilinia laxa*, *Penicillium digitatum*, *Penicillium italicum*, *Penicillium expansum*, *Phomopsis viticola*, *Podosphaera leucotricha*, *Podosphaera xanthii*, *Pseudopezicula tracheiphila*, *Septoria tritici*, *Uncinula necator* and *Venturia inaequalis*.

Preferred is a method of controlling or preventing phytopathogenic diseases, especially

15 phytopathogenic fungi, which comprises applying a composition according to the invention to useful plants selected from the group consisting of grains, fruits and tree nuts, vegetables, field crops, oil seed crops, forage crops, forest plants, horticulture crops, floriculture, greenhouse and nursery plants, propagative materials, culinary herbs and spices, and medicinal herbs.

More preferred is a method of controlling or preventing phytopathogenic diseases, especially

20 phytopathogenic fungi, which comprises applying a composition according to the invention to useful plants selected from the group consisting of wheat, barley, rice, soybean, apples, almonds, cherries, raspberries, grapes, cucumbers, peanuts, tomatoes, strawberries, citrus and bananas.

In an embodiment of the invention, the method of controlling or preventing phytopathogenic diseases according to the invention may be particularly effective against phytopathogenic fungi

25 selected from the group consisting of *Alternaria*, *Cercospora*, *Colletotrichum*, *Corynespora*, *Mycosphaerella*, *Phakopsora*, *Phomopsis* and *Septoria* on soybean plants.

In an embodiment of the invention, the method of controlling or preventing phytopathogenic diseases according to the invention may be particularly effective against phytopathogenic fungi selected from the group consisting of *Alternaria spp.*, *Cercospora kikuchii*, *Cercospora soja*, *Phakopsora pachyrhizi* and *Septoria glycines* on soybean plants.

30

The invention also provides fungicidal compositions comprising a combination of components (A) and (B) as mentioned above in a synergistically effective amount, together with an agriculturally acceptable carrier and, optionally, a surfactant. In said compositions, the weight ratio of (A) to (B) is preferably from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200,

35 even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1 as described hereinbefore.

It has been found, surprisingly, that certain weight ratios of component (A) to component (B) are able to give rise to synergistic activity. Therefore, a further aspect of the invention are compositions, wherein component (A) and component (B) are present in the composition in amounts producing a synergistic effect. This synergistic activity is apparent from the fact that the fungicidal activity of the composition comprising component (A) and component (B) is greater than the sum of the fungicidal activities of component (A) and component (B). This synergistic activity extends the range of action of component (A) and component (B) in two ways. Firstly, the rates of application of component (A) and component (B) are lowered whilst the action remains equally good, meaning that the active ingredient mixture still achieves a high degree of phytopathogen control even where the two individual components have become totally ineffective in such a low application rate range. Secondly, there is a substantial broadening of the spectrum of phytopathogens that can be controlled.

A synergistic effect exists whenever the action of an active ingredient combination is greater than the sum of the actions of the individual components. The action to be expected E for a given active ingredient combination obeys the so-called COLBY formula and can be calculated as follows (COLBY, S.R. "Calculating synergistic and antagonistic responses of herbicide combination", Weeds, Vol. 15, pages 20-22; 1967):

ppm = milligrams of active ingredient (= a.i.) per liter of spray mixture,
X = % action by active ingredient (A) using p ppm of active ingredient,
Y = % action by active ingredient (B) using q ppm of active ingredient.

According to COLBY, the expected (additive) action of active ingredients (A)+(B) using p+q ppm

of active ingredient is

$$E = X + Y - \frac{X \cdot Y}{100}$$

If the action actually observed (O) is greater than the expected action (E), then the action of the combination is super-additive, i.e. there is a synergistic effect. In mathematical terms, synergism corresponds to a positive value for the difference of (O-E). In the case of purely complementary addition of activities (expected activity), said difference (O-E) is zero. A negative value of said difference (O-E) signals a loss of activity compared to the expected activity.

However, besides the actual synergistic action with respect to fungicidal activity, the compositions according to the invention can also have further surprising advantageous properties. Examples of such advantageous properties that may be mentioned are: more advantageous degradability; improved toxicological and/or ecotoxicological behaviour; or improved characteristics of the useful plants including: emergence, crop yields, more developed root system, tillering increase, increase in plant height, bigger leaf blade, less dead basal leaves, stronger tillers, greener leaf colour, less fertilizers needed, less seeds needed, more productive tillers, earlier flowering, early grain

maturity, less plant verse (lodging), increased shoot growth, improved plant vigor, and early germination.

The Examples which follow serve to illustrate the invention and are not meant in any way to limit the invention.

BIOLOGICAL EXAMPLES

The compositions according to the invention are tested for their biological (fungicidal) activity using application rates wherein the component (A) is applied at a rate of from 25 g a.i./ha to 500 g a.i./ha in association with 10 g a.i./ha to 500 g a.i./ha of component (B).

The compositions according to the invention are tested for their biological (fungicidal) activity as dimethylsulfoxide (DMSO) solutions the protocols as set forth in the examples below. A standard description of the liquid culture tests is provided in Example 1.

Aureobasidin A and its synthesis are known from Takesako et al., *The Journal of Antibiotics*, 1991, 44, 919-924. Aureobasidin A is separated from the fermentation broth by extraction with ethyl acetate, followed by extraction of the ethyl acetate concentrate with a mixture of MeOH:H₂O (80% by volume) and cyclohexane (20% by volume), and purified by silica gel column chromatography (silica-gel, elution with hexane:ethyl acetate) followed by reverse phase column chromatography (RP18, elution with acetonitrile:H₂O). As already indicated, components (B) of the compositions are known and are commercially available and/or can be prepared using procedures known in the art and/or procedures reported in the literature.

Example 1: Liquid culture tests in well plates

Compounds to be tested were prepared as DMSO solutions (max. 10 mg/mL) which were diluted to the appropriate concentration with 0.025% TWEEN 20® surfactant just before spraying. Soybean leaf disks were placed on agar in multiwell plates (24-well format) and sprayed with test solutions. After 24 hours drying, the leaf disks were inoculated with a spore suspension of the fungus. The disease severity of a compound or mixture was assessed 12 days after inoculation and described as percent activity relative to the untreated check leaf disks.

RESULTS

Results from the tests outlined above are shown below in Tables 1 to 8. These data show that synergistic fungicidal activity is observed for the combination of Aureobasidin A and another active ingredient of component (B) against Asian soybean rust caused by *Phakopsora pachyrhizi* on soybean at certain weight ratios.

According to COLBY, in mathematical terms the synergism factor (SF) corresponds to O/E. In the agricultural practice an SF of > 1.0 indicates significant improvement over the purely complementary addition of activities (expected activity), while an SF of ≤ 0.9 in the practical application routine signals a loss of activity compared to the expected activity.

5

Table 1: Fungicidal activity of a composition of Aureobasidin A and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate (B.01) against *Phakospora pachyrhizi* on soybean as described in Example 1 above.

Aureobasidin A (A) (ppm)	B.01 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
2.5	-		62			
-	0.74			50		
2.5	0.74	3.3:1			81	95
7.4	0.74	10:1			94	100

10

Table 2: Fungicidal activity of a composition of Aureobasidin A and N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide (B.02) against *Phakospora pachyrhizi* on soybean as described in Example 1 above.

Aureobasidin A (A) (ppm)	B.02 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
2.5	-		62			
-	2.22			35		
-	0.74			10		
7.4	2.22	3.3:1			92	95
2.5	0.74	3.3:1			66	70
7.4	0.74	10:1			90	95

15

Table 3: Fungicidal activity of a composition of Aureobasidin A and N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide (B.03) against *Phakospora pachyrhizi* on soybean as described in Example 1 above.

Aureobasidin A (A) (ppm)	B.03 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
-	2.22			35		

-	0.74			10		
7.4	2.22	3.3:1			92	100
7.4	0.74	10:1			90	95

Table 4: Fungicidal activity of a composition of Aureobasidin A and N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide (B.04) against *Phakospsora pachyrhizi* on soybean as described in Example 1 above.

5

Aureobasidin A (A) (ppm)	B.04 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
2.5	-		62			
-	2.22			35		
-	0.74			0		
-	0.25			0		
7.4	2.22	3.3:1			92	100
2.5	0.74	3.3:1			62	90
7.4	0.74	10:1			88	95
2.5	0.25	10:1			62	70

Table 5: Fungicidal activity of a composition of Aureobasidin A and 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea (B.05) against *Phakospsora pachyrhizi* on soybean as described in Example 1 above.

10

Aureobasidin A (A) (ppm)	B.05 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
2.5	-		62			
-	0.74			50		
-	0.25			0		
2.5	0.74	3.3:1			81	90
2.5	0.25	10:1			62	70

Table 6: Fungicidal activity of a composition of Aureobasidin A and 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea (B.06) against *Phakospsora pachyrhizi* on soybean as described in Example 1 above.

15

Aureobasidin A (A) (ppm)	B.06 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
2.5	-		62			

-	0.74			0		
-	0.25			0		
2.5	0.74	3.3:1			62	80
7.4	0.74	10:1			88	100
2.5	0.25	10:1			62	70

Table 7: Fungicidal activity of a composition of Aureobasidin A and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea (B.07) against *Phakospora pachyrhizi* on soybean as described in Example 1 above.

5

Aureobasidin A (A) (ppm)	B.07 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
2.5	-		62			
-	0.74			35		
-	0.25			0		
2.5	0.74	3.3:1			75	90
7.4	0.74	10:1			92	100
2.5	0.25	10:1			62	80


Table 8: Fungicidal activity of a composition of Aureobasidin A and N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (B.08) against *Phakospora pachyrhizi* on soybean as described in Example 1 above.

10

Aureobasidin A (A) (ppm)	B.08 (B) (ppm)	Ratio compound (A):(B)	(A) inhibition (%)	(B) inhibition (%)	Expected (additive) activity (Colby) (%)	Combined inhibition (observed) (%)
7.4	-		88			
2.5	-		62			
-	2.22			60		
-	0.74			20		
-	0.25			0		
7.4	2.22	3.3:1			95	100
2.5	0.74	3.3:1			69	80
7.4	0.74	10:1			91	100
2.5	0.25	10:1			62	80

CLAIMS

1. A fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) comprises a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof:




(I-A1); and

component (B) is selected from the group consisting of histone deacetylase inhibitors:

ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate, N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(E)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-

- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(Z)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoic acid, ethyl 1-[[4-[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazole-4-carboxylate, or ethyl 1-[[4-[[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carboxylate, or a salt, enantiomer, tautomer or N-oxide thereof.
2. The composition according to claim 1, wherein the weight ratio of (A) to (B) is from 100:1 to 1:1000, preferably from 100:1 to 1:500, more preferably from 50:1 to 1:200, even more preferably from 50:1 to 1:20, still more preferably from 30:1 to 1:1, still more preferably from 10:1 to 3:1.
3. The composition according to claim 1 or claim 2, wherein component (A) further comprises one or more other cyclic depsipeptides of formula (I-A) different from Aureobasidin A or stereoisomers thereof:



wherein

R¹ is methyl or ethyl;

each of X¹, X² and X³ is hydrogen, or X¹, X² and X³ are hydrogen, fluorine or hydroxyl, with the proviso that only one of X¹, X² and X³ is fluorine or hydroxyl;


X⁴ is S, methylene or hydroxymethylene;

A³ is an α -amino acid residue selected from the group consisting of N-methyl-L-phenylalanine (L-MePhe), L-phenylalanine (L-Phe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), ortho-fluoro-N-methyl-L-phenylalanine (L-o-F-MePhe), meta-fluoro-N-methyl-L-phenylalanine (L-m-F-MePhe), para-fluoro-N-methyl-L-phenylalanine (L-p-F-MePhe), meta-bromo-N-methyl-L-

- phenylalanine (L-m-Br-MePhe), para-bromo-N-methyl-L-phenylalanine (L-p-Br-MePhe), meta-iodo-N-methyl-L-phenylalanine (L-m-I-MePhe), para-iodo-N-methyl-L-phenylalanine (L-p-I-MePhe), 3-phenyl-N-methyl-L-phenylalanine, 4-phenyl-N-methyl-L-phenylalanine, 3-(4-fluorophenyl)-N-methyl-L-phenylalanine, 4-(4-fluorophenyl)-N-methyl-L-phenylalanine, 3-(4-pyridinyl)-N-methyl-L-phenylalanine, 4-(4-pyridinyl)-N-methyl-L-phenylalanine, 3-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(1-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-4-pyridinyl)-N-methyl-L-phenylalanine, 3-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 4-(2-chloro-5-pyridinyl)-N-methyl-L-phenylalanine, 3-[4-(piperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(piperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine, 3-[4-(4-methylpiperazin-1-yl)phenyl]phenyl-N-methyl-L-phenylalanine, 4-[4-(4-methylpiperazin-1-yl)phen-1-yl]phenyl-N-methyl-L-phenylalanine, β -oxo-N-methyl-L-phenylalanine (L- β -oxo-MePhe), β -acetoxo-N-methyl-L-phenylalanine (L- β -AcO-MePhe), N-methyl-L-tyrosine (L-MeTyr), O-methyl-N-methyl-L-tyrosine [L-MeTyr(Me)], N-methyl-L-alanine (L-MeAla), N-methyl-L-serine (L-MeSer), N-methyl-D-phenylalanine (D-MePhe), N-methyl-D-alanine (D-MeAla), N-methyl-D-valine (D-MeVal), N-methyl-D-serine (D-MeSer) and N-methyl-L-serine (L-MeSer) residues;
- A⁵ is an α -amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle), L-norvaline (L-Nva) and L-valine (L-Val) residues;
- A⁶ is an α -amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), N-methyl-L-allo-isoleucine (L-MeAlle) and L-valine (L-Val) residues;
- A⁷ is an α -amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and
- A⁸ is an α -amino acid residue selected from the group consisting of β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal), γ -hydroxy-N-methyl-L-valine (L- γ -OH-MeVal), N-methyl-L-valine (L-MeVal), L-valine (L-Val), N-methyl-2,3-didehydro-L-valine (L-MeDH_{2,3}Val), N-methyl-3,4-didehydro-L-valine (L-MeDH_{3,4}Val), N-methyl-L-phenylalanine (L-MePhe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), N-methyl-L-threonine (L-MeThr), sarcosine (Sar) and N, β -dimethyl-L-aspartic acid (L-N, β -MeAsp) residues.
4. The composition according to any one of claims 1 to 3, wherein component (A) further comprises Aureobasidin E and/or Aureobasidin G.
5. The composition according to any one of claims 1 to 4, wherein component (A) comprises: from 10% to 99.9% by weight, preferably from 20% to 99.9% by weight, more preferably from 40% to 99.9% by weight of a cyclic depsipeptide of formula (I-A1) or a stereoisomer thereof, and

from 0.1% to 90% by weight, preferably from 0.1% to 80% by weight, more preferably from 0.1% to 60% by weight of one or more other cyclic depsipeptides of formula (I-A) different from Aureobasidin A or stereoisomers thereof.

- 5 6. The composition according to any one of claims 1 to 5, wherein component (A) further comprises one or more cyclic depsipeptides of formula (I-B) or stereoisomers thereof:



- 10 wherein
- R¹ is methyl or ethyl;
- X⁴ is S, methylene or hydroxymethylene;
- A⁵ is an α -amino acid residue selected from the group consisting of L-allo-isoleucine (L-Alle), L-leucine (L-Leu), L-norleucine (L-Nle) and L-valine (L-Val) residues;
- 15 A⁶ is an α -amino acid residue selected from the group consisting of N-methyl-L-valine (L-MeVal), N-methyl-L-leucine (L-MeLeu), L-allo-isoleucine (L-Alle) and N-methyl-L-allo-isoleucine (L-MeAlle) residues;
- A⁷ is an α -amino acid residue selected from the group consisting of L-leucine (L-Leu), L-allo-isoleucine (L-Alle) and L-norvaline (L-Nva) residues; and
- 20 A⁸ is an α -amino acid residue selected from the group consisting of β -hydroxy-N-methyl-L-valine (L- β -OH-MeVal), γ -hydroxy-N-methyl-L-valine (L- γ -OH-MeVal), N-methyl-L-valine (L-MeVal), N-methyl-2,3-didehydro-L-valine (L-MeDH_{2,3}Val), N-methyl-3,4-didehydro-L-valine (L-MeDH_{3,4}Val), N-methyl-L-phenylalanine (L-MePhe), β -hydroxy-N-methyl-L-phenylalanine (L- β -OH-MePhe), N-

methyl-L-threonine (L-MeThr), sarcosine (Sar) and N, β -dimethyl-L-aspartic acid (L-N, β -MeAsp) residues.

- 5 7. The composition according to any one of claims 1 to 6, further comprising an agriculturally acceptable carrier and/or formulation adjuvant, and optionally, a surfactant.
8. A method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition as defined in any one of claims 1 to 7.
- 10 9. The method according to claim 8, wherein the component (A) is applied at a rate of from 25 g a.i./ha to 500 g a.i./ha in association with 10 g a.i./ha to 500 g a.i./ha of component (B).
- 15 10. The method according to claim 8 or claim 9, wherein the phytopathogenic fungi are selected from the group consisting of *Alternaria*, *Botrytis*, *Cercospora*, *Colletotrichum*, *Corynespora*, *Guignardia*, *Mycosphaerella*, *Monilinia*, *Penicillium*, *Phakopsora*, *Phomopsis*, *Podosphaera*, *Pseudopezizicola*, *Septoria*, *Uncinula* and *Venturia*.
- 20 11. The method according to any one of claims 8 to 10, wherein the useful plant is selected from grains, fruits and tree nuts, vegetables, field crops, oil seed crops, forage crops, forest plants, horticulture crops, floriculture, greenhouse and nursery plants, propagative materials, culinary herbs and spices, and medicinal herbs.
- 25 12. The method according to any one of claims 8 to 11, wherein the useful plant is selected from the group consisting of wheat, barley, rice, soybean, apples, almonds, cherries, raspberries, grapes, cucumbers, peanuts, tomatoes, strawberries, citrus and bananas.
- 30 13. The method according to any one of claims 8 to 12, wherein said method controls or prevents phytopathogenic fungi selected from the group consisting of *Alternaria*, *Cercospora*, *Colletotrichum*, *Corynespora*, *Mycosphaerella*, *Phakopsora*, *Phomopsis* and *Septoria* on soybean plants.
- 35 14. The method according to any one of claims 8 to 13, wherein the components (A) and (B) as defined in any one of claims 1 to 7 are applied in a sequential manner.
15. Use of a composition comprising component (A) and component (B) as defined in any one of claims 1 to 7 as a fungicide.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2022/082228

A. CLASSIFICATION OF SUBJECT MATTER		
INV.	A01N37/46	A01N43/72
	A01N53/00	A01P3/00
ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
A01N A01P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 500 264 A1 (TAKARA SHUZO CO LTD) 26 August 1992 (1992-08-26) claims examples	1-15
Y	WO 2018/102345 A1 (AGROBIOLOGICS LLC [US]) 7 June 2018 (2018-06-07) cited in the application claims examples	1-15
	----- -/--	
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
2 February 2023		13/02/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Galley, Carl

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2022/082228

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ALIMEHR SHADI ET AL: "Antifungal Activity of Aureobasidin A in Combination with Fluconazole against Fluconazole-Resistant Candida albicans", INFECTION EPIDEMIOLOGY AND MICROBIOLOGY , vol. 6, no. 4 1 January 2020 (2020-01-01), pages 285-291, XP055909479, ISSN: 2588-4107, DOI: 10.29252/iem.6.4.285 Retrieved from the Internet: URL:https://iem.modares.ac.ir/browse.php?a_code=A-10-11249-5&sid=4&slc_lang=en&ftxt=1&pure_pdf=1 abstract -----	1-15
Y	WO 2017/118689 A1 (SYNGENTA PARTICIPATIONS AG [CH]) 13 July 2017 (2017-07-13) claims examples -----	1-15
A	DAISUKE MURAMATSU ET AL: "Aureobasidium pullulans produced &#946;-glucan is effective to enhance Kurosengoku soybean extract induced Thrombospondin-1 expression", SCIENTIFIC REPORTS, vol. 7, no. 1, 6 June 2017 (2017-06-06), XP055511623, DOI: 10.1038/s41598-017-03053-9 the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/082228

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0500264	A1	26-08-1992	DE 69206007 T2 25-07-1996
		EP 0500264 A1	26-08-1992
		ES 2079793 T3	16-01-1996

WO 2018102345	A1	07-06-2018	NONE

WO 2017118689	A1	13-07-2017	BR 112018013821 A2 11-12-2018
		CL 2018001859 A1	31-08-2018
		CN 108463460 A	28-08-2018
		CO 2018007065 A2	19-07-2018
		EP 3400223 A1	14-11-2018
		IL 259985 A	31-07-2018
		JP 6937760 B2	22-09-2021
		JP 2019506381 A	07-03-2019
		US 2019297892 A1	03-10-2019
		US 2021037826 A1	11-02-2021
		UY 37062 A	31-08-2017
		WO 2017118689 A1	13-07-2017
		ZA 201804214 B	24-04-2019
